U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H19N5
Molecular Weight 269.3449
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIZATRIPTAN

SMILES

CN(C)CCC1=CNC2=CC=C(CN3C=NC=N3)C=C12

InChI

InChIKey=ULFRLSNUDGIQQP-UHFFFAOYSA-N
InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00953 | https://www.drugs.com/pro/rizatriptan-orally-disintegrating-tablets.html | http://reference.medscape.com/drug/maxalt-maxalt-mlt-rizatriptan-343033 | https://www.ncbi.nlm.nih.gov/pubmed/9357514

Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches. Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches. Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors. Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Rizatriptan benzoate presumably exerts its therapeutic effects in the treatment of a migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system. Rizatriptan is completely absorbed following oral administration. The mean oral absolute bioavailability of the rizatriptan benzoate tablet is about 45%, and mean peak plasma concentrations are reached in approximately 1-1.5 hours. The presence of a migraine headache did not appear to affect the absorption or pharmacokinetics of rizatriptan. Food has no significant effect on the bioavailability of rizatriptan but delays the time to reach peak concentration by an hour. The primary route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not active at the 5-HT1B/1D receptor. N-mono-desmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-mono-desmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT1B/1D receptor.

Originator

Curator's Comment: # Merck Sharp and Dohme Ltd.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.1 nM [Ki]
3.0 nM [EC50]
140.0 nM [Ki]
7.9 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXALT

Approved Use

MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.

Launch Date

1998
Primary
MAXALT

Approved Use

MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.

Launch Date

1998
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.8 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.2 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
54 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
6.1 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
12.7 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.2 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
27.29 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
28.6 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
127 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
161 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
19 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
33 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
42 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
68 ng × h/mL
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
69.88 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
72 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
84 ng × h/mL
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
97 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.1 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.4 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.2 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.2 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.4 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.9 h
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.4 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.4 h
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.6 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIZATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg single, oral
Recommended
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Other AEs: Jaundice...
Other AEs:
Jaundice
Sources:
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 25 years
n = 2
Health Status: unhealthy
Age Group: 25 years
Sex: M
Population Size: 2
Sources:
Other AEs: Syncope, Incontinence...
Other AEs:
Syncope (1 patient)
Incontinence (1 patient)
Sources:
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 25-29 years
n = 2
Health Status: unhealthy
Age Group: 25-29 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Dizziness...
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 29 years
n = 2
Health Status: unhealthy
Age Group: 29 years
Sex: F
Population Size: 2
Sources:
Other AEs: Vomiting, Bradycardia...
Other AEs:
Vomiting (1 patient)
Bradycardia (1 patient)
Sources:
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
tacrolimus(8.5 mg/day; oral)
Sources:
unhealthy, 43 years
n = 1
Health Status: unhealthy
Age Group: 43 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Transient ischemic attack...
AEs leading to
discontinuation/dose reduction:
Transient ischemic attack
Sources:
AEs

AEs

AESignificanceDosePopulation
Jaundice
10 mg single, oral
Recommended
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Incontinence 1 patient
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 25 years
n = 2
Health Status: unhealthy
Age Group: 25 years
Sex: M
Population Size: 2
Sources:
Syncope 1 patient
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 25 years
n = 2
Health Status: unhealthy
Age Group: 25 years
Sex: M
Population Size: 2
Sources:
Dizziness 2 patients
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 25-29 years
n = 2
Health Status: unhealthy
Age Group: 25-29 years
Sex: M+F
Population Size: 2
Sources:
Bradycardia 1 patient
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 29 years
n = 2
Health Status: unhealthy
Age Group: 29 years
Sex: F
Population Size: 2
Sources:
Vomiting 1 patient
80 mg single, oral
Overdose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
unhealthy, 29 years
n = 2
Health Status: unhealthy
Age Group: 29 years
Sex: F
Population Size: 2
Sources:
Transient ischemic attack Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
tacrolimus(8.5 mg/day; oral)
Sources:
unhealthy, 43 years
n = 1
Health Status: unhealthy
Age Group: 43 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Comparative aspects of triptans in treating migraine.
2001
Rizatriptan: pharmacological differences from sumatriptan and clinical results.
2001
Sumatriptan: pharmacological basis and clinical results.
2001
Acute treatment of migraine and the role of triptans.
2001 Mar
Evidence-based migraine therapy.
2001 Nov
Cluster headache without autonomic symptoms?
2001 Nov
Clinical features of withdrawal headache following overuse of triptans and other headache drugs.
2001 Nov 13
[Cost effectiveness of treatment with triptanes in Spain].
2001 Nov 16-30
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
2001 Nov 17
[Therapy of an acute migraine attack. Uniform patient vote for rizatriptan].
2001 Nov 22
Triptans in the treatment of basilar migraine and migraine with prolonged aura.
2001 Nov-Dec
Advances in pharmacological treatment of migraine.
2001 Oct
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
2002
Spotlight on rizatriptan in migraine.
2002
Rizatriptan: an update of its use in the management of migraine.
2002
Gateways to Clinical Trials.
2002 Apr
[Satisfaction and recovery of normal activity with rizatriptan 10 mg. Results from the open, prospective, observational 4M study].
2002 Dec
Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial.
2002 Fall
Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain.
2002 Feb
Migraine: diagnosis, management, and new treatment options.
2002 Feb
Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor.
2002 Feb 1
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.
2002 Jan
Treatment of migraine with rizatriptan: when to take the medication.
2002 Jan
Tripstar: a comprehensive patient-based approach to compare triptans.
2002 Jan
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.
2002 Jul
Pharmacological treatments for acute migraine: quantitative systematic review.
2002 Jun
CNS effects of sumatriptan and rizatriptan in healthy female volunteers.
2002 May
[Controlling migraine with highly effective triptanes. Lowers rate of drug use].
2002 May 6
[Good ruler for assessing effectiveness. Pain free with only one tablet].
2002 May 6
[New meta-analysis of triptanes. Concrete help, so the choice doesn't become overwhelming].
2002 May 6
Sum of Pain Intensity Differences (SPID) in migraine trials. A comment based on four rizatriptan trials.
2002 Oct
Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
2002 Oct
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
2002 Sep 10
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
2002 Sep 10
Newer formulations of the triptans: advances in migraine management.
2003
Pharmacological approaches to migraine.
2003
Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
2003
Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.
2003 Apr
[New therapeutic recommendations for severe migraine. High beginning dosage rather than slow dosage increase].
2003 Jan 30
Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours.
2003 Jan-Feb
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
2003 Jul
Real-world experiences in migraine therapy with rizatriptan.
2003 Mar
[Highly selective beginning. Associated symptoms and side effects in retrospect].
2003 May 26
An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.
2003 Nov
Rizatriptan RPD for severe migraine in the emergency department--a multicenter study.
2003 Oct
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
2004 Feb
Evaluating triptan usage.
2004 Feb
Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
2004 Jan
Neuronal expression and regulation of CGRP promoter activity following viral gene transfer into cultured trigeminal ganglia neurons.
2004 Jan 30
Fast onset medications through thermally generated aerosols.
2004 May
Patents

Sample Use Guides

5-10 mg PO at onset of symptoms; repeat dose after 2 hours if necessary; not to exceed 30 mg/24 hr
Route of Administration: Oral
In Vitro Use Guide
Rizatriptan intrinsic efficacy, expressed as percent of the maximal 5-HT response, was measured in cloned human 5-HT1D and 5-HT1B receptors stably expressed in CHO cells using agonist-induced [35S]GTPγS binding. In this assay, interaction of the agonist-occupied receptor with the G-protein results in dissociation of GDP from the G-protein R-subunit and the binding of a molecule of GTP. Under normal conditions the R-subunit dissociates from the âγ-subunits and, following modulation of its effector, intrinsic R-subunit GTPase hydrolyzes the GTP to GDP. Because [35S]GTPγS is resistant to this GTPase, it accumulates in the membrane and it can be measured by virtue of its radiolabel
Name Type Language
RIZATRIPTAN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
RIZATRIPTAN [MI]
Common Name English
MK-462 FREE BASE
Code English
Rizatriptan [WHO-DD]
Common Name English
rizatriptan [INN]
Common Name English
L-705126
Code English
RIZATRIPTAN [VANDF]
Common Name English
1H-INDOLE-3-ETHANAMINE, N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000175765
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
NCI_THESAURUS C47794
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
NDF-RT N0000175764
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
WHO-ATC N02CC04
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
NDF-RT N0000175763
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
WHO-VATC QN02CC04
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
LIVERTOX 857
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
Code System Code Type Description
SMS_ID
100000080246
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
NCI_THESAURUS
C61930
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
MERCK INDEX
m9640
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY Merck Index
FDA UNII
51086HBW8G
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
DRUG CENTRAL
2393
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
DAILYMED
51086HBW8G
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
EVMPD
SUB10346MIG
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
LACTMED
Rizatriptan
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
MESH
C093622
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
WIKIPEDIA
Rizatriptan
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL905
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
PUBCHEM
5078
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
DRUG BANK
DB00953
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID2023565
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
CHEBI
48273
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
RXCUI
88014
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY RxNorm
IUPHAR
51
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
CAS
144034-80-0
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY
INN
7474
Created by admin on Fri Dec 15 15:53:26 GMT 2023 , Edited by admin on Fri Dec 15 15:53:26 GMT 2023
PRIMARY